Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Denmark: COPSAC, Copenhagen Prospective Study of Childhood Asthma, researchers in Copenhagen, Denmark, noted that a higher risk...
Read Full NewsClinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.
Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.
Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.
The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.
1.
New protein target discovered for childhood medulloblastomas
2.
Effects of Recombinant Replacement Therapy Explained in Detailed Regarding Genetic Clotting Disorder.
3.
Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases
4.
PFS in R/R Mantle Cell Lymphoma is Improved by Ibrutinib-Venetoclax.
5.
'Ray of hope': New developments in the fight against various cancers.
1.
PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision
2.
Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment
3.
Colon Cancer Staging: What You Need to Know
4.
The Benefits and Side Effects of Bortezomib in the Fight Against Cancer
5.
Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Thromboprophylaxis In Medical Settings
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge